The equine mesenchymal stromal cell (MSC) secretome modulates neutrophils and monocyte-derived macrophages and extracellular vesicles (EVs) impact macrophage viability.
Rajesh A., Harman RM., Van de Walle GR.
Animal Study, published in Vet Immunol Immunopathol (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Vet Immunol Immunopathol (2026)
- Country
- Netherlands
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42546424
- DOI
- 10.1016/j.vetimm.2026.111185
Abstract (original English)
Neutrophil chemotaxis and phagocytosis are critical for protection against bacteria, but can be compromised by methicillin-resistant Staphylococcus aureus (MRSA). MRSA can also circumvent macrophage surveillance by affecting polarization and reactive oxygen species (ROS) production. We previously demonstrated that the secretome of equine mesenchymal stromal cells (MSCs), comprised of all secreted bioactive factors and collected as conditioned medium (CM), reduces the growth of MRSA both in vitro and in vivo. This study aimed to determine if the equine MSC secretome has additional anti-MRSA properties by studying its effects on equine neutrophil and macrophage functions in vitro. Transwell assays demonstrated that CM from adipose tissue- and bone marrow-, but not peripheral blood-, derived MSCs significantly enhanced neutrophil migration. In addition, CM from all three MSC sources significantly reduced the phagocytic capacity of neutrophils but did not alter ROS production. MSC CM from all three tissue sources promoted macrophage polarization toward both CD86-positive (M1-like) and CD206-positive (M2-like) phenotypes, but did not change phagocytic capacity or ROS production. Further experiments showed that the complete CM, rather than the soluble and extracellular vesicle (EV) subfractions, was responsible for the increased neutrophil chemotaxis. Additionally, the primary effect
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.